JP2018500012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018500012A5 JP2018500012A5 JP2017526681A JP2017526681A JP2018500012A5 JP 2018500012 A5 JP2018500012 A5 JP 2018500012A5 JP 2017526681 A JP2017526681 A JP 2017526681A JP 2017526681 A JP2017526681 A JP 2017526681A JP 2018500012 A5 JP2018500012 A5 JP 2018500012A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- gene
- human
- polypeptide
- humanized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087992P | 2014-12-05 | 2014-12-05 | |
| US62/087,992 | 2014-12-05 | ||
| PCT/US2015/062614 WO2016089692A1 (en) | 2014-12-05 | 2015-11-25 | Non-human animals having a humanized cluster of differentiation 47 gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114628A Division JP7089554B2 (ja) | 2014-12-05 | 2020-07-02 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018500012A JP2018500012A (ja) | 2018-01-11 |
| JP2018500012A5 true JP2018500012A5 (OSRAM) | 2018-12-13 |
| JP6730277B2 JP6730277B2 (ja) | 2020-07-29 |
Family
ID=54979926
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526681A Active JP6730277B2 (ja) | 2014-12-05 | 2015-11-25 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
| JP2020114628A Active JP7089554B2 (ja) | 2014-12-05 | 2020-07-02 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020114628A Active JP7089554B2 (ja) | 2014-12-05 | 2020-07-02 | ヒト化されたcluster of differentiation 47遺伝子を有する非ヒト動物 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US20160345549A1 (OSRAM) |
| EP (4) | EP3086637B1 (OSRAM) |
| JP (2) | JP6730277B2 (OSRAM) |
| KR (3) | KR102313073B1 (OSRAM) |
| CN (2) | CN107205368B (OSRAM) |
| AR (1) | AR102888A1 (OSRAM) |
| AU (2) | AU2015355328B2 (OSRAM) |
| BR (1) | BR112017010490A2 (OSRAM) |
| CA (1) | CA2967834C (OSRAM) |
| CY (2) | CY1121547T1 (OSRAM) |
| DK (3) | DK3466255T3 (OSRAM) |
| ES (3) | ES2969389T3 (OSRAM) |
| FI (1) | FI3850946T3 (OSRAM) |
| HR (3) | HRP20231707T1 (OSRAM) |
| HU (3) | HUE043132T2 (OSRAM) |
| IL (2) | IL286403B2 (OSRAM) |
| LT (3) | LT3466255T (OSRAM) |
| MX (1) | MX2017007293A (OSRAM) |
| NZ (2) | NZ731471A (OSRAM) |
| PL (3) | PL3086637T3 (OSRAM) |
| PT (3) | PT3466255T (OSRAM) |
| RS (3) | RS58536B1 (OSRAM) |
| RU (1) | RU2728412C2 (OSRAM) |
| SG (2) | SG11201703463WA (OSRAM) |
| SI (3) | SI3086637T1 (OSRAM) |
| SM (3) | SMT202300482T1 (OSRAM) |
| TR (1) | TR201903891T4 (OSRAM) |
| TW (1) | TWI681053B (OSRAM) |
| WO (1) | WO2016089692A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3086637B1 (en) | 2014-12-05 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 47 gene |
| MX2017007636A (es) | 2014-12-09 | 2018-03-28 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado. |
| WO2016154299A1 (en) * | 2015-03-24 | 2016-09-29 | The Trustees Of Columbia University In The City Of New York | Genetic modification of pigs for xenotransplantation |
| KR102377189B1 (ko) | 2015-05-29 | 2022-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | C9orf72 유전자좌에서 파괴를 갖는 비-인간 동물 |
| AU2016358101B2 (en) | 2015-11-20 | 2022-12-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized Lymphocyte-activation gene 3 |
| KR102487839B1 (ko) | 2016-02-04 | 2023-01-12 | 리제너론 파마슈티칼스 인코포레이티드 | 조작된 angptl8 유전자를 갖는 비인간 동물 |
| SG10202001578RA (en) | 2016-02-29 | 2020-04-29 | Regeneron Pharma | Rodents having a humanized tmprss gene |
| EP4056031A1 (en) * | 2016-08-11 | 2022-09-14 | The Jackson Laboratory | Methods and compositions relating to improved human red blood cell survival in genetically modified immunodeficient non-human animals |
| CN107815465B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| WO2018041121A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ctla-4 |
| US11279948B2 (en) | 2016-08-31 | 2022-03-22 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric OX40 |
| CN107815468B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| EP3518667B1 (en) * | 2016-09-30 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Rodents having a hexanucleotide repeat expansion in a c9orf72 locus |
| CN108467873B (zh) | 2017-03-17 | 2020-03-13 | 百奥赛图江苏基因生物技术有限公司 | 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用 |
| WO2018177441A1 (en) | 2017-03-31 | 2018-10-04 | Beijing Biocytogen Co., Ltd | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα |
| CN108588126B (zh) | 2017-03-31 | 2020-04-10 | 北京百奥赛图基因生物技术有限公司 | Cd47基因人源化改造动物模型的制备方法及应用 |
| GB2588249B (en) * | 2017-06-12 | 2023-01-04 | Sinai Health Sys | Allograft tolerance without the need for systemic immune suppression |
| EP3661965A4 (en) | 2017-08-02 | 2022-07-13 | Phanes Therapeutics, Inc. | ANTI-CD47 ANTIBODIES AND USES THEREOF |
| CA3076377A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized trkb locus |
| CA3093850A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| SMT202400300T1 (it) | 2018-07-16 | 2024-09-16 | Regeneron Pharma | Modelli di roditori della sindrome ditra e loro utilizzo |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113423831B (zh) | 2018-12-20 | 2023-03-10 | 瑞泽恩制药公司 | 核酸酶介导的重复扩增 |
| CN111218425B (zh) * | 2019-01-17 | 2022-02-08 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
| WO2021027737A1 (en) * | 2019-08-09 | 2021-02-18 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric il2ra |
| US20220346357A1 (en) * | 2019-09-06 | 2022-11-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric tnfr2 |
| CN113122574A (zh) * | 2019-12-31 | 2021-07-16 | 百奥赛图(北京)医药科技股份有限公司 | 一种免疫缺陷型人源化非人动物的构建方法 |
| CN112080522A (zh) * | 2020-09-15 | 2020-12-15 | 广东药康生物科技有限公司 | 一种cd47人源化小鼠模型的构建方法 |
| CN112725379B (zh) * | 2021-01-27 | 2024-08-13 | 上海南方模式生物科技股份有限公司 | 人源化cd40基因改造动物模型的构建方法及应用 |
| CN116064558A (zh) * | 2021-09-24 | 2023-05-05 | 百奥赛图(北京)医药科技股份有限公司 | Trop2基因人源化非人动物的构建方法及应用 |
| KR20250040674A (ko) | 2022-07-19 | 2025-03-24 | 리제너론 파마슈티칼스 인코포레이티드 | 유전적으로 변형된 동물 모델 및 인간 면역 시스템을 모델링하는데 있어서 그것의 용도 |
| US20250255282A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670356A (en) | 1994-12-12 | 1997-09-23 | Promega Corporation | Modified luciferase |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2545166A1 (en) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| PL2767161T3 (pl) | 2004-10-19 | 2018-09-28 | Regeneron Pharmaceuticals, Inc. | Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej |
| WO2007033221A2 (en) * | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| CA2661848C (en) * | 2006-09-01 | 2015-02-03 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| WO2009039244A2 (en) * | 2007-09-18 | 2009-03-26 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| CN101668387A (zh) | 2008-09-02 | 2010-03-10 | 鸿富锦精密工业(深圳)有限公司 | 印刷电路板 |
| WO2010082385A1 (ja) * | 2009-01-16 | 2010-07-22 | 財団法人実験動物中央研究所 | ヒト肝細胞が移植されたマウス |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| WO2011020005A1 (en) | 2009-08-14 | 2011-02-17 | Regeneron Pharmaceuticals, Inc. | miRNA-REGULATED DIFFERENTIATION-DEPENDENT SELF-DELETING CASSETTE |
| US8758750B2 (en) * | 2009-09-15 | 2014-06-24 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-CD47 therapy for hematologic cancers |
| ES3010323T3 (en) | 2009-10-06 | 2025-04-02 | Regeneron Pharma | Genetically modified mice and engraftment |
| KR102714361B1 (ko) | 2011-02-15 | 2024-10-11 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 m-csf 마우스 |
| US20140242095A1 (en) * | 2011-10-19 | 2014-08-28 | University Health Network | Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers |
| KR101926442B1 (ko) | 2011-10-28 | 2018-12-12 | 리제너론 파아마슈티컬스, 인크. | 키메라 주요 조직적합성 복합체 (mhc) ii 분자들을 발현하는 유전자 변형된 마우스 |
| PL2663575T3 (pl) | 2011-10-28 | 2015-03-31 | Regeneron Pharma | Humanizowane IL-6 i receptor IL-6 |
| DK2770821T3 (da) | 2011-10-28 | 2017-11-27 | Regeneron Pharma | Genetisk modificerede major histocompatibility-kompleks-mus |
| EP2644027A1 (en) * | 2012-03-26 | 2013-10-02 | Institut Pasteur | Transgenic immunodefficient mouse expressing human SIRPalpha. |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| KR102473555B1 (ko) | 2012-09-07 | 2022-12-05 | 예일 유니버시티 | 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법 |
| IL311744B2 (en) | 2012-11-05 | 2025-10-01 | Regeneron Pharma | Genetically modified non-human animals and methods of using them |
| BR112015013431A2 (pt) * | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
| LT2958938T (lt) | 2013-02-20 | 2019-07-25 | Regeneron Pharmaceuticals, Inc. | Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius |
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| PT4269430T (pt) | 2013-09-23 | 2025-08-06 | Regeneron Pharma | Animais não-humanos com um gene humanizado de proteína reguladora de sinal |
| EP3138397B1 (en) | 2013-10-15 | 2018-12-26 | Regeneron Pharmaceuticals, Inc. | Humanized il-15 animals |
| MX356809B (es) | 2013-11-19 | 2018-06-13 | Regeneron Pharma | Animales no humanos que tienen un gen del factor activador de celulas b. |
| EP3071025B1 (en) | 2013-11-19 | 2018-10-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| RU2700484C2 (ru) | 2014-04-08 | 2019-09-17 | Регенерон Фармасьютикалз, Инк. | Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы |
| NO2785538T3 (OSRAM) | 2014-05-07 | 2018-08-04 | ||
| KR20250096864A (ko) | 2014-05-19 | 2025-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
| CN106604635B (zh) | 2014-06-19 | 2020-01-14 | 瑞泽恩制药公司 | 具有人源化程序性细胞死亡1基因的非人动物 |
| DK3223605T3 (da) | 2014-11-24 | 2020-11-16 | Regeneron Pharma | Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks |
| EP3086637B1 (en) | 2014-12-05 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 47 gene |
-
2015
- 2015-11-25 EP EP15813960.0A patent/EP3086637B1/en active Active
- 2015-11-25 PL PL15813960T patent/PL3086637T3/pl unknown
- 2015-11-25 PL PL20215046.2T patent/PL3850946T3/pl unknown
- 2015-11-25 PL PL18207075T patent/PL3466255T3/pl unknown
- 2015-11-25 EP EP23192469.7A patent/EP4296278A3/en active Pending
- 2015-11-25 CA CA2967834A patent/CA2967834C/en active Active
- 2015-11-25 LT LTEP18207075.5T patent/LT3466255T/lt unknown
- 2015-11-25 SM SM20230482T patent/SMT202300482T1/it unknown
- 2015-11-25 KR KR1020177013948A patent/KR102313073B1/ko active Active
- 2015-11-25 SG SG11201703463WA patent/SG11201703463WA/en unknown
- 2015-11-25 PT PT182070755T patent/PT3466255T/pt unknown
- 2015-11-25 BR BR112017010490A patent/BR112017010490A2/pt not_active Application Discontinuation
- 2015-11-25 NZ NZ731471A patent/NZ731471A/en unknown
- 2015-11-25 HR HRP20231707TT patent/HRP20231707T1/hr unknown
- 2015-11-25 WO PCT/US2015/062614 patent/WO2016089692A1/en not_active Ceased
- 2015-11-25 JP JP2017526681A patent/JP6730277B2/ja active Active
- 2015-11-25 HU HUE15813960A patent/HUE043132T2/hu unknown
- 2015-11-25 DK DK18207075.5T patent/DK3466255T3/da active
- 2015-11-25 SI SI201530659T patent/SI3086637T1/sl unknown
- 2015-11-25 CN CN201580066047.0A patent/CN107205368B/zh active Active
- 2015-11-25 KR KR1020237007814A patent/KR102617691B1/ko active Active
- 2015-11-25 DK DK20215046.2T patent/DK3850946T5/da active
- 2015-11-25 ES ES20215046T patent/ES2969389T3/es active Active
- 2015-11-25 SI SI201531599T patent/SI3466255T1/sl unknown
- 2015-11-25 EP EP18207075.5A patent/EP3466255B1/en active Active
- 2015-11-25 LT LTEP20215046.2T patent/LT3850946T/lt unknown
- 2015-11-25 PT PT202150462T patent/PT3850946T/pt unknown
- 2015-11-25 KR KR1020217032415A patent/KR102508175B1/ko active Active
- 2015-11-25 HU HUE18207075A patent/HUE054661T2/hu unknown
- 2015-11-25 RS RS20190370A patent/RS58536B1/sr unknown
- 2015-11-25 IL IL286403A patent/IL286403B2/en unknown
- 2015-11-25 AU AU2015355328A patent/AU2015355328B2/en active Active
- 2015-11-25 CN CN202011160730.XA patent/CN112342197B/zh active Active
- 2015-11-25 DK DK15813960.0T patent/DK3086637T3/en active
- 2015-11-25 FI FIEP20215046.2T patent/FI3850946T3/fi active
- 2015-11-25 RS RS20231251A patent/RS64989B1/sr unknown
- 2015-11-25 SM SM20190178T patent/SMT201900178T1/it unknown
- 2015-11-25 PT PT15813960T patent/PT3086637T/pt unknown
- 2015-11-25 TR TR2019/03891T patent/TR201903891T4/tr unknown
- 2015-11-25 RU RU2017123357A patent/RU2728412C2/ru active
- 2015-11-25 SG SG10202103050YA patent/SG10202103050YA/en unknown
- 2015-11-25 NZ NZ769992A patent/NZ769992A/en unknown
- 2015-11-25 SI SI201531982T patent/SI3850946T1/sl unknown
- 2015-11-25 LT LTEP15813960.0T patent/LT3086637T/lt unknown
- 2015-11-25 RS RS20210547A patent/RS61774B1/sr unknown
- 2015-11-25 US US14/951,825 patent/US20160345549A1/en not_active Abandoned
- 2015-11-25 EP EP20215046.2A patent/EP3850946B1/en active Active
- 2015-11-25 HU HUE20215046A patent/HUE064960T2/hu unknown
- 2015-11-25 HR HRP20190634TT patent/HRP20190634T1/hr unknown
- 2015-11-25 ES ES15813960T patent/ES2716735T3/es active Active
- 2015-11-25 ES ES18207075T patent/ES2870462T3/es active Active
- 2015-11-25 SM SM20210281T patent/SMT202100281T1/it unknown
- 2015-11-25 MX MX2017007293A patent/MX2017007293A/es unknown
- 2015-12-03 AR ARP150103952A patent/AR102888A1/es unknown
- 2015-12-03 TW TW104140456A patent/TWI681053B/zh active
-
2016
- 2016-01-19 US US15/000,751 patent/US10015953B2/en active Active
-
2017
- 2017-04-30 IL IL252019A patent/IL252019B/en unknown
-
2018
- 2018-05-17 US US15/982,174 patent/US10939673B2/en active Active
-
2019
- 2019-03-21 CY CY20191100334T patent/CY1121547T1/el unknown
-
2020
- 2020-07-02 JP JP2020114628A patent/JP7089554B2/ja active Active
-
2021
- 2021-01-29 US US17/161,801 patent/US11910788B2/en active Active
- 2021-04-27 HR HRP20210662TT patent/HRP20210662T1/hr unknown
- 2021-05-06 CY CY20211100382T patent/CY1124089T1/el unknown
-
2022
- 2022-06-02 AU AU2022203787A patent/AU2022203787B2/en active Active
-
2024
- 2024-01-16 US US18/413,219 patent/US12389889B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018500012A5 (OSRAM) | ||
| JP7649370B2 (ja) | 抗kras-g12d t細胞受容体 | |
| Ma et al. | Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth | |
| AU2017355218B2 (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| JP2023017834A (ja) | 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節 | |
| JP2019047818A5 (OSRAM) | ||
| JP7611836B2 (ja) | 抗原特異的t細胞の同定のための組成物と方法 | |
| ES3037239T3 (en) | Non-human animals having a humanized signal-regulatory protein gene | |
| JP2021166522A (ja) | キメラ抗原受容体組成物 | |
| RU2017123357A (ru) | Животные, отличные от человека, имеющие гуманизированный ген кластера дифференцировки 47 | |
| JP2018500896A5 (OSRAM) | ||
| CA2959821A1 (en) | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance | |
| HRP20200613T1 (hr) | Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt | |
| WO2016023001A1 (en) | Multispecific high affinity pd-1 agents and methods of use | |
| US20170267755A1 (en) | Isolated anti-mesothelin antibodies, conjugates and uses thereof | |
| JP2016514099A5 (OSRAM) | ||
| JP2017521060A5 (OSRAM) | ||
| CN109152837A (zh) | 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法 | |
| JP6630026B1 (ja) | 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー | |
| CN114207117A (zh) | 用于调节巨噬细胞活性的方法 | |
| KR20190027832A (ko) | 향상된 효능을 갖는 치료를 위한 질병-특이적 표적으로서 네오에피토프의 선택 | |
| CN111629715A (zh) | 通过调节细胞活化状态改变体内免疫细胞的炎症状态 | |
| KR20200104282A (ko) | 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법 | |
| KR102581970B1 (ko) | 면역 부전 마우스 | |
| JP2011200233A5 (OSRAM) |